Trial Profile

A Phase I/II Clinical Study on the Safety, Tolerability and Preliminary Efficacy of C019199 in Combination With Sintilimab in Patients With Advanced Solid Tumors

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 09 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs C 019199 (Primary) ; Sintilimab (Primary)
Indications Cervical cancer; Colorectal cancer; Gastric cancer; Head and neck cancer; Non-small cell lung cancer; Oesophageal cancer; Pancreatic cancer; Solid tumours; Squamous cell cancer; Triple negative breast cancer
Focus Adverse reactions; Therapeutic Use
Sponsors Fujian Haixi Pharmaceuticals

Most Recent Events

04 Jun 2024 Results (As of Jan 15, 2024, n=10) assessing safety and efficacy of C019199 in combination with sintilimab in advanced malignancy presented at the 60th Annual Meeting of the American Society of Clinical Oncology
30 Jan 2024 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com